肺炎克雷伯菌
鲍曼不动杆菌
微生物学
碳青霉烯
抗生素
β-内酰胺酶抑制剂
不动杆菌
医学
内酰胺
抗生素耐药性
头孢菌素
生物
细菌
铜绿假单胞菌
化学
大肠杆菌
遗传学
基因
立体化学
作者
Christina Koenig,Joseph L. Kuti
摘要
Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of β-lactamases diminishing the activity of classic β-lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of β-lactamase inhibitors (BLIs) with activity against extended-spectrum β-lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo-β-lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem-resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various β-lactamases including MBL and OXA-enzymes.
科研通智能强力驱动
Strongly Powered by AbleSci AI